모더나, 노년층 대상 코로나19 백신 실험 성과<br /><br />Moderna's potential COVID-19 vaccine has reportedly generated a promising immune response in elderly patients in an early stage clinical trial.<br />The biotech firm said Wednesday that its vaccine was tested on ten adults between the ages of 56 and 70 and ten elderly adults aged 71 and older.<br />The volunteers produced T-cells and neutralizing antibodies, which researchers believe are necessary to build immunity against the virus.<br />Additionally, the antibodies that were produced were higher than those seen in people who have recovered from COVID-19.<br />
